Analyst Report: AMGN

1. EXECUTIVE SUMMARY

Amgen Inc. (AMGN) suffered a dramatic 13.63% plunge over the past week, falling from over $442 to close at $382.47 on September 10, 2026. The sell-off was triggered by a "perfect storm" of negative pipeline and regulatory catalysts. Primarily, Novartis announced a devastating Phase III failure for its cardiovascular drug pelacarsen, entirely undermining the clinical thesis for Amgen's own multi-billion-dollar pipeline asset, olpasiran, which targets the exact same Lp(a) pathway. Compounding this pipeline blow, UK regulators suspended new-patient use of Amgen's rare-disease drug Tavneos over data integrity concerns, mirroring recent EU and US FDA actions. In response, major Wall Street firms including BMO Capital and HSBC swiftly downgraded AMGN. This steep drop reflects an abrupt repricing of Amgen's future growth engine against a backdrop of mature product biosimilar threats.

2. THE CATALYST (CRITICAL)

The -13.63% decline was driven by three specific, converging events in early September 2026:

• Pelacarsen Phase III Failure & Olpasiran Read-Through (September 4, 2026): Swiss rival Novartis (NVS) announced that its investigational Lp(a)-lowering drug pelacarsen failed its pivotal Phase III cardiovascular outcomes study. Despite successfully lowering Lp(a) levels, it did not reduce the risk of cardiovascular death, heart attacks, or strokes. Because Amgen's highly anticipated pipeline drug olpasiran utilizes the exact same mechanism of action, investors heavily discounted its future commercial viability, viewing the entire Lp(a) drug class as scientifically impaired.
• Analyst Downgrades (September 8 & 10, 2026): BMO Capital downgraded AMGN from "Outperform" to "Market Perform" on September 8, explicitly citing the Novartis trial failure lowering expectations for olpasiran. On September 10, HSBC followed suit, downgrading Amgen from "Buy" to "Hold" and cutting its price target from $445 to $425.
• Tavneos Regulatory Suspensions (September 1, 2026): The UK's Medicines and Healthcare products Regulatory Agency (MHRA) suspended new-patient use of Amgen's rare-disease drug Tavneos, stating the main study supporting its approval was unreliable. The MHRA plans to revoke UK approval entirely by March 2027. This follows the European Commission revoking its EU marketing authorization in August and the US FDA proposing a U.S. withdrawal due to data integrity and liver injury concerns.

3. COMPANY PROFILE

• Official Company Name: Amgen Inc.
• Core Business: Amgen is a pioneering multinational biopharmaceutical company that discovers, develops, manufactures, and delivers human therapeutics. Its portfolio focuses heavily on cardiovascular disease, oncology, bone health, and inflammatory conditions, with blockbuster products including Enbrel, Prolia, Xgeva, and Repatha.
• Market Cap: ~$211.5 Billion (as of September 10, 2026)
• Sector & Industry: Healthcare / Biotechnology
• Key Competitors: Novartis, AbbVie, Johnson & Johnson, Pfizer, Merck, Eli Lilly
• Recent Performance Context: Prior to this sell-off, AMGN had been a top sector performer, rallying over 36% year-to-date into early September on the back of raised 2026 guidance and obesity pipeline hype. It was trading near its 52-week high of $447.03 before plunging to a recent close of $382.47. The current 52-week range is $269.77 to $447.03.

4. DEEP DIVE ANALYSIS

• Is this move justified? The multi-billion dollar market cap wipeout is largely fundamentally justified. Amgen has been trading at a premium multiple (trailing P/E ~24x) because the market baked in future revenues from clinical assets like olpasiran (Lp(a)) to offset looming biosimilar cliffs for aging blockbusters like Prolia, Xgeva, and Enbrel. With olpasiran severely de-risked by a direct competitor's failure, and Tavneos (acquired via the $3.7B buyout of ChemoCentryx in 2022) facing global regulatory withdrawal, Amgen's terminal pipeline growth rate has been meaningfully impaired.
• Historical & Sector Context: Biotech stocks routinely face 10-15% haircuts on late-stage clinical failures. However, for a mega-cap defensive pharma name like Amgen, a drop of this magnitude is historically rare and highlights just how much of the stock's recent 52-week run was tied to pipeline optimism. Sector-wide, Novartis (NVS) and its partner Ionis (IONS) also plummeted on the pelacarsen news.
• Bull Case: Amgen's core commercial portfolio remains highly robust. Q2 2026 revenues topped $10 billion (up 10% YoY) with 22 products posting double-digit growth. Commercial drivers like Repatha and Tezspire are thriving, and the company confirmed at the Sept 10 Wells Fargo Healthcare Conference that it intends to maintain operating margins of 45-46%. Bulls will view this 13.6% haircut as a derisking event that offers an attractive entry point for a stock yielding ~2.5%.
• Bear Case: The loss of the Lp(a) cardiovascular market is a massive blow to the long-term thesis. Biosimilar competition is accelerating globally, and if the FDA proceeds with a full US withdrawal of Tavneos, Amgen will be forced to write off a large portion of its $3.7B ChemoCentryx acquisition. Furthermore, with olpasiran in doubt, an outsized amount of pipeline pressure now rests on MariTide, Amgen's experimental obesity drug. Any clinical hiccups there could trigger a much steeper structural re-rating.

5. TECHNICAL SNAPSHOT

• Support/Resistance Levels:
  • Support: $380 (Near-term psychological floor and September 10 low of $381.51); $365 (GuruFocus intrinsic value estimate zone).
  • Resistance: $410 (Bottom of the massive September 8 gap-down); $425 (New HSBC price target); $447 (Recent 52-week highs).
• Volume Analysis: The breakdown was convicted. On September 8, when the stock dropped over 10% in a single session, volume exploded to 6.83 million shares—more than 3x the 20-day average volume of ~2 million shares. This heavy volume indicates aggressive institutional distribution rather than retail panic.
• Chart Patterns: AMGN suffered a severe "gap down" pattern. Prior to September 4, the stock was in a tight volatility compression phase near $440. The chart now reflects a broken uptrend with heavy overhead supply trapped between $410 and $440.

6. RISK FACTORS

• FDA Final Decision on Tavneos: While UK and EU regulators have already pulled the plug on Tavneos for new patients, the U.S. FDA's final decision is pending. An outright U.S. ban would wipe out $450M+ in annual run-rate revenue and destroy the remaining value of the ChemoCentryx acquisition.
• Pipeline Concentration Risk: With the Lp(a) cardiovascular thesis wounded, Amgen's valuation is increasingly dependent on the success of its obesity asset MariTide and oncology assets like tarlatamab.
• Upcoming Catalysts to Watch:
  • FDA formal hearing and ruling on Tavneos (Date TBD).
  • Updates from the Morgan Stanley Global Healthcare Conference (September 15, 2026).
  • Q3 2026 Earnings Report (Late October / Early November 2026).

7. ACTIONABLE OUTLOOK

• Short-term (1-2 weeks): Neutral to Bearish. Expect choppy consolidation in the $375-$395 range. The technical damage is severe, and the massive breakaway gap created on September 8 will act as heavy overhead resistance, capping near-term upside.
• Medium-term (1-3 months): Neutral. Investor focus will aggressively pivot to Amgen's Q3 earnings execution and MariTide clinical updates. Management must prove that current commercial engines (Repatha, Tezspire) can sustain double-digit growth to offset the sentiment drag created by the pipeline failures.
• Long-term thesis: Fundamentally Altered, But Intact. Amgen remains a cash-flow behemoth with a sustainable 2.5% dividend yield and a strong core portfolio. However, the "growth premium" previously assigned to its pipeline has been permanently impaired by the olpasiran read-through and Tavneos disaster. Investors must recalibrate expectations, valuing AMGN as a mature, defensive biopharma navigating patent cliffs rather than a high-flying growth stock.